Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials

被引：0
作者：
Kyaw Zin Thein
Thura Win Htut
Somedeb Ball
Sriman Swarup
Anita Sultan
Thein Hlaing Oo
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics
[2] University of Aberdeen,Department of Hematology, Aberdeen Royal Infirmary Hospital
[3] Texas Tech University Health Sciences Center,Department of Internal Medicine
[4] Texas Tech University Health Sciences Center,Department of Hematology/Oncology
[5] The University of Texas MD Anderson Cancer Center,Section of Benign Hematology
来源：
Breast Cancer Research and Treatment | 2020年 / 183卷
关键词：
Metastatic breast cancer; Venous thromboembolism; Hormone receptor-positive HER2-negative; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：479 / 487
页数：8
相关论文
共 50 条
[31]   CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all? [J].
Fedele, Palma ;
Cinieri, Saverio .
FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) :1237-1239
[32]   Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis [J].
Ergun, Yakup ;
Dogan, Mutlu ;
Ucar, Gokhan ;
Karacin, Pinar ;
Karacin, Cengiz .
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (17) :1901-1909
[33]   Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study [J].
Li, Doudou ;
Jin, Yizi ;
Lin, Mingxi ;
Zeng, Cheng ;
Guo, Qing ;
Liu, Yanfei ;
Zhang, Jian .
CANCER MEDICINE, 2024, 13 (04)
[34]   First-line endocrine therapy for hormone receptor positive and HER-2 negative metastatic breast cancer: A Bayesian network meta-analysis [J].
Jiang, Yi-Cheng ;
Yang, Jing-Jing ;
Zhang, Hai-Tian ;
Zhuo, Rui ;
de la Roche, Sebastian ;
de la Roche, Luz Angela ;
De Wilde, Rudy Leon ;
Dong, Jie .
ONCOLOGY LETTERS, 2024, 28 (05)
[35]   Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy [J].
Harbeck, Nadia ;
Kates, Ronald ;
Schinkoethe, Timo ;
Schumacher, Johannes ;
Wuerstlein, Rachel ;
Degenhardt, Tom ;
Lueftner, Diana ;
Raeth, Philip ;
Hoffmann, Oliver ;
Lorenz, Ralf ;
Decker, Thomas ;
Reinisch, Mattea ;
Goehler, Thomas ;
Staib, Peter ;
Gluz, Oleg ;
Fasching, Peter A. ;
Schmidt, Marcus .
CANCER TREATMENT REVIEWS, 2023, 121
[36]   Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer [J].
Sahin, Taha Koray ;
Rizzo, Alessandro ;
Guven, Deniz Can ;
Aksoy, Sercan .
CANCER TREATMENT REVIEWS, 2025, 135
[37]   CDK4/6 inhibitors for primary endocrine resistant HR-positive/ HER2-negative metastatic breast cancer: a case report [J].
Luo, Ting ;
Zhu, Kunrui ;
Zhong, Xiaorong ;
He, Ping ;
Yan, Xi ;
Tian, Tinglun .
TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
[38]   Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study [J].
Fedele, Palma ;
Landriscina, Matteo ;
Moraca, Lucia ;
Cusmai, Antonio ;
Gnoni, Antonio ;
Licchetta, Antonella ;
Guarini, Chiara ;
Lanotte, Laura ;
Pappagallo, Maria Nicla ;
Melaccio, Assunta ;
Giordano, Guido ;
Maselli, Felicia Maria ;
Pinto, Antonello ;
Giuliani, Francesco ;
Chiuri, Vincenzo ;
Giotta, Francesco ;
Gadaleta-Caldarola, Gennaro .
CANCERS, 2024, 16 (20)
[39]   Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients’ experiences [J].
Helena Harder ;
Rachel Starkings ;
Lesley Fallowfield ;
Shirley May ;
Valerie Shilling .
Supportive Care in Cancer, 2025, 33 (5)
[40]   Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis [J].
Ayer Botrel, Tobias Engel ;
Paladini, Luciano ;
Clark, Otyvio Augusto C. .
CORE EVIDENCE, 2013, 8 :69-78
12345